SP2509: Selective LSD1 Antagonist for Acute Myeloid Leukemia Research

Executive Summary: SP2509 is a novel, highly selective inhibitor of lysine-specific demethylase 1 (LSD1) with an IC50 of 13 nM in biochemical assays (APExBIO). It does not inhibit monoamine oxidases MAO-A or MAO-B at relevant concentrations. In pre-clinical acute myeloid leukemia (AML) models, SP2509 induces apoptosis, promotes differentiation, and increases survival in xenograft mice (Ivyspring 2021). The compound acts through disruption of the LSD1-CoREST complex, leading to increased H3K4 trimethylation and reactivation of tumor suppressor genes. SP2509 is a solid compound with a molecular weight of 437.90, insoluble in water and ethanol, but highly soluble in DMSO. It is intended for scientific research use only, not for diagnostic or medical purposes.

Biological Rationale

Lysine-specific demethylase 1 (LSD1/KDM1A) is an epigenetic regulator that demethylates mono- and di-methylated lysine 4 on histone H3 (H3K4me1/2). This reaction is linked to repression of transcription for target genes (Ivyspring 2021). Overexpression of LSD1 is observed in multiple cancers, including AML, and correlates with poor patient prognosis. The LSD1-CoREST complex is required for efficient demethylation and gene silencing. Targeting LSD1 is a validated approach for reactivating silenced tumor suppressor genes and modifying the malignant phenotype.

Mechanism of Action of SP2509

SP2509, developed and distributed by APExBIO, is a reversible, non-covalent antagonist of LSD1. The compound binds the FAD-dependent amine oxidase domain of LSD1, preventing demethylation of H3K4me1/2. Its IC50 is 13 nM under standard in vitro conditions (pH 7.4, DMSO, 25°C) (APExBIO).

• SP2509 does not inhibit MAO-A or MAO-B, ensuring high selectivity for LSD1.
• Disruption of the LSD1-CoREST complex by SP2509 leads to increased H3K4 trimethylation (H3K4Me3) at promoter regions.
• This epigenetic shift reactivates tumor suppressor genes including p53, p21, and C/EBPα, restoring cell cycle control and apoptosis pathways.

SP2509’s mechanism contrasts with DNA methyltransferase inhibitors by specifically modulating histone methylation, offering a targeted approach to epigenetic therapy in AML.

Evidence & Benchmarks

• SP2509 demonstrates potent inhibition of LSD1 enzymatic activity with an IC50 of 13 nM in biochemical assays (APExBIO).
• In human AML cell lines (OCI-AML3, MOLM13), SP2509 reduces colony formation and induces apoptosis at concentrations ≥100 nM (24–72 h, in vitro) (Ivyspring 2021).
• SP2509 treatment promotes myeloid differentiation in cultured and primary AML cells, as assessed by CD11b upregulation (flow cytometry, 48 h) (Ivyspring 2021).
• In NOD/SCID mice bearing human AML xenografts, intraperitoneal dosing of SP2509 (25 mg/kg, twice weekly) significantly extends median survival compared to vehicle (p<0.05) (Ivyspring 2021).
• Combination therapy with SP2509 and the pan-HDAC inhibitor panobinostat produces synergistic effects, further improving survival in mouse AML models (Ivyspring 2021).

Applications, Limits & Misconceptions

SP2509 is widely used in pre-clinical AML research to dissect the role of histone demethylation in oncogenesis and therapy resistance. It is also valuable for studies in cancer epigenetics and drug synergy testing with HDAC inhibitors.

For practical insights on experimental design and reproducibility, see Enhancing AML Research with SP2509, which details scenario-driven guidance and extends this article by focusing on data-driven laboratory implementation.

Common Pitfalls or Misconceptions

• SP2509 is not effective in cancers lacking LSD1 overexpression or where LSD1 is not a driver of malignancy.
• It does not inhibit DNA methylation; its effects are specific to histone H3K4 demethylation.
• SP2509 is not a suitable monoamine oxidase inhibitor and should not be used for studies on MAO-A/MAO-B pathways.
• Long-term storage of SP2509 solutions is not recommended due to compound instability; use freshly prepared solutions.
• SP2509 is for research use only and not approved for diagnostic or therapeutic applications in humans.

Workflow Integration & Parameters

SP2509 (SKU: B4894) is supplied as a solid by APExBIO (product page). The compound has a molecular weight of 437.90 and chemical formula C₁₉H₂₀ClN₃O₅S. It is insoluble in water and ethanol, but dissolves readily in DMSO at ≥19.45 mg/mL. For improved solubility, gentle warming to 37°C or use of an ultrasonic bath is effective. Store at −20°C. Solutions should be used promptly; do not store long-term in solution form.

Recommended in vitro working concentrations range from 10 nM to 1 μM, depending on cell type and endpoint. For in vivo use, preclinical studies employ 25 mg/kg administered intraperitoneally twice per week in NOD/SCID mice. SP2509 can be combined with panobinostat or other epigenetic modulators for synergy studies.

For more detailed practical protocols and troubleshooting, refer to the internal resource Enhancing AML Research with SP2509, which clarifies optimal handling and experimental reproducibility strategies beyond the core mechanism-focused content here.

Conclusion & Outlook

SP2509 is a validated, potent, and selective LSD1 antagonist supporting advanced research in AML and cancer epigenetics. Its impact lies in the targeted disruption of histone demethylation and reactivation of tumor suppressor pathways. As a research tool, SP2509 enables precise interrogation of LSD1’s role in malignancy and offers a platform for combination strategies with HDAC inhibitors. Future directions include broader applications across LSD1-driven malignancies and refinement of dosing regimens for optimized in vivo efficacy. For technical specifications, ordering, and further details, refer to the official APExBIO SP2509 product page.